You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亿帆医药(002019.SZ):麻芩消咳颗粒及复方黄黛片纳入国家医保目录
格隆汇 11-29 19:16

格隆汇11月29日丨亿帆医药(002019.SZ)公布,2019年11月28日,国家医保局、人力资源社会保障部印发《关于将2019年谈判药品纳入乙类范围的通知》,将97种谈判药品纳入了《国家基本医疗保险、工伤保险和生育保险药品目录(2019年版)》。公司独家医保及基本药物目录产品复方黄黛片通过谈判续约再次纳入《国家医保目录》;公司独家产品麻芩消咳颗粒首次纳入《国家医保目录》。

公司独家产品复方黄黛片于2009年由原国家食品药品监督管理总局批准上市,是依据“君、臣、佐、史”原则配伍制定的治疗急性早幼粒细胞白血病(以下简称“APL”)的特效药产品,疗效显著、可靠,为治疗白血病的主要用药之一,是中国APL诊治指南的推荐药物;同时作为口服制剂,无需住院治疗,可简化治疗,减少毒副作用,改善患者长期预后、提高生存质量并降低整体治疗费用,使APL患者最大程度地长期受益。复方黄黛片于2011年获得国家科技进步二等奖,是中国目前为数不多的在《新英格兰医学杂志》、《美国国家科学院院刊》、《临床肿瘤学杂志》等国际学术期刊上发表研究成果的复方中药制剂产品;砷剂联合维甲酸治疗APL是中国医生及科学家对世界的贡献并已经成为世界公认的经典方案。

麻芩消咳颗粒系公司全资子公司天长亿帆制药有限公司生产的治疗急性支气管炎、慢性支气管炎急性发作属痰热郁肺证的原中药三类新药产品。药品来源于安徽省名老中医的临床经验方,以“麻杏石甘汤”为基础加减而成,上市前已在临床应用多年,经过系统的药理毒理研究和临床研究,疗效确切,安全可靠。纯中药成份,无药物依赖性及成瘾性,安全性好。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account